A national surveillance system for continuous monitoring of blood transfusion safety: German haemovigilance data

Abstract Background and Objectives Haemovigilance (HV) systems aim to improve transfusion outcomes in patients and donor safety. An important question for blood regulators is how to ensure an effective HV system. Materials and Methods We retrospectively analysed the HV reports submitted to Paul‐Ehrlich‐Institut over the last two decades. Results Between 2011 and 2020, 50.86 million units of blood components were used, and 8931 suspected serious donor and recipient adverse reactions (SARs), 874 serious adverse events (SAEs) and 12,073 donor look‐backs were reported. Following implementation of specific risk‐minimization measures (RMMs) between 2000 and 2010, SAR reporting rates decreased for transfusion‐transmitted viral infections (TTVIs), transfusion‐related acute lung injury (TRALI) and transfusion‐transmitted bacterial infections (TTBIs), while increasing for other serious adverse transfusion reactions. Within this decade, the overall blood component use decreased. Conclusion Long‐term data collection forms the basis to establish trends and changes in reporting and to evaluate the effect of RMM. Standardized criteria for reaction types, seriousness and imputability assessments and availability of a denominator are important elements. Central data collection and independent assessment allow for monitoring HV data in a nationwide context over time. Stakeholder involvement and transparent feedback on the benefit of RMM will help to achieve the objectives of HV.